These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11701896)

  • 61. [Comparison of the biological availability of levodopa in the preparations Dopaflex and Nakom in patients with parkinson disease].
    Terziivanov D; Havlík I; Stika L; Janků I
    Cesk Farm; 1984 Feb; 33(1):20-3. PubMed ID: 6529759
    [No Abstract]   [Full Text] [Related]  

  • 62. Twentieth WFN World Congress on Parkinson's disease and related disorders.
    Frei K; Wolters ECh
    Expert Rev Neurother; 2014 Jul; 14(7):741-3. PubMed ID: 24852108
    [No Abstract]   [Full Text] [Related]  

  • 63. Parkinsonism and Dementia: Synucleinopathies, Tauopathies and Beyond. Proceedings of a workshop. Istanbul, Turkey, 9-11 May 2002.
    Mov Disord; 2003 Sep; 18 Suppl 6():S1-98. PubMed ID: 14502649
    [No Abstract]   [Full Text] [Related]  

  • 64. [Oxidative stress and Parkinson's disease: mechanisms and perspectives of treatment].
    Katunina EA; Titova NV; Malykhina EA; Gasanov MG; Makarova AA; Voronina TA; Nerobkova LN; Valdman EA; Avakyan GN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(7):141-145. PubMed ID: 26356527
    [No Abstract]   [Full Text] [Related]  

  • 65. Endogenous dopamine release in Parkinson's disease.
    Rinne JO
    Lancet Neurol; 2003 Aug; 2(8):460-1. PubMed ID: 12878432
    [No Abstract]   [Full Text] [Related]  

  • 66. Parkinson's Disease: The Life Cycle of the Dopamine Neuron. September 18-20, 2002. Princeton, New Jersey, USA. Proceedings.
    Ann N Y Acad Sci; 2003 Jun; 991():1-360. PubMed ID: 12846968
    [No Abstract]   [Full Text] [Related]  

  • 67. Problems with traffic ahead: Synaptic vesicles in Parkinson's disease.
    Pifl C
    Mov Disord; 2016 Oct; 31(10):1480. PubMed ID: 27477200
    [No Abstract]   [Full Text] [Related]  

  • 68. DNA tetrahedral nanocages as a promising nanocarrier for dopamine delivery in neurological disorders.
    Singh R; Kansara K; Yadav P; Mandal S; Varshney R; Gupta S; Kumar A; Maiti PK; Bhatia D
    Nanoscale; 2024 Aug; 16(32):15158-15169. PubMed ID: 39091152
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Levodopa.
    Muenter MD
    Ann Intern Med; 1971 Nov; 75(5):795-7. PubMed ID: 5001133
    [No Abstract]   [Full Text] [Related]  

  • 70. Parkinson's vaccine on trial.
    Pilcher H
    Lancet Neurol; 2005 Aug; 4(8):458-9. PubMed ID: 16086492
    [No Abstract]   [Full Text] [Related]  

  • 71. Oxidative damage and cytogenic analysis in leukocytes of Parkinson's disease patients.
    Leblhuber F; Neurauter G; Fuchs D
    Neurology; 2003 Feb; 60(4):729; author reply 729. PubMed ID: 12601131
    [No Abstract]   [Full Text] [Related]  

  • 72. Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Adler CH; Dugger BN; Hentz JG; Hinni ML; Lott DG; Driver-Dunckley E; Mehta S; Serrano G; Sue LI; Duffy A; Intorcia A; Filon J; Pullen J; Walker DG; Beach TG
    Mov Disord; 2017 May; 32(5):722-723. PubMed ID: 28513078
    [No Abstract]   [Full Text] [Related]  

  • 73. Response to "Potential Role of N-Acetyl Cysteine in the Cysteine Proteome in Parkinson's Disease?".
    Monti DA; Newberg AB
    Clin Pharmacol Ther; 2020 May; 107(5):1056. PubMed ID: 31823347
    [No Abstract]   [Full Text] [Related]  

  • 74. Lasers aimed at mad cows.
    Trends Mol Med; 2001 Jan; 7(1):11. PubMed ID: 11427975
    [No Abstract]   [Full Text] [Related]  

  • 75. Parkinson's disease.
    Dinges J
    Curr Top Med Chem; 2009; 9(10):854. PubMed ID: 19754399
    [No Abstract]   [Full Text] [Related]  

  • 76. Aggregate formation and the structure of the aggregates of disulfide-reduced proteins.
    Takase K; Higashi T; Omura T
    J Protein Chem; 2002 Aug; 21(6):427-33. PubMed ID: 12492154
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 78. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Conway KA; Rochet JC; Bieganski RM; Lansbury PT
    Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
    Lotharius J; Brundin P
    Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550
    [No Abstract]   [Full Text] [Related]  

  • 80. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
    Li J; Zhu M; Manning-Bog AB; Di Monte DA; Fink AL
    FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.